2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Lymphomas, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult
PAPER

5386 Risk of second primary solid malignancies among diffuse large B-cell lymphoma survivors in the United States

Merry Zhai, MD, Kristy Bono, MD2, Safia Ansari, DO3, Anand Shah, MBBS4, Joshua Kra, MD5
1 Rutgers New Jersey Medical School, Newark, New Jersey, United States
2 Rutgers New Jersey Medical School, Newark, New Jersey, United States
3 Rutgers New Jersey Medical School, Newark, New Jersey, United States
4 Rutgers New Jersey Medical School, Newark, New Jersey, United States
5 Rutgers New Jersey Medical School, Newark, New Jersey, United States

Introduction:
Survivors of Diffuse Large B-cell Lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, are living substantially longer due to the development and adoption of more effective therapies. With improving survival, patients with DLBCL face an elevated risk of developing second primary malignancies (SPMs). The risk of SPMs may vary over time and can inform SPM mitigation, surveillance, and early intervention. This study aimed to estimate the standardized incidence ratios of SPMs among DLBCL survivors in the United States.

Methods:
We used data from the Surveillance, Epidemiology and End Results Program (SEER)-12 registry to identify individuals diagnosed with DLBCL between 2000 and 2022. Solid-tumor SPMs diagnosed at least six months after the initial DLBCL diagnosis were included and categorized typographically using ICD-O codes. SPMs diagnosed <6 months from index date were excluded to reduce surveillance bias associated with the medical assessments at time of cancer diagnosis. Using patient’s age, sex, and race/ethnicity, we calculated standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) for each SPM across four-time intervals: 6–11 months, 12–59 months, 60–119 months, and ≥120 months post-diagnosis. We conducted separate models estimating overall solid tumor SIRs by sex, race, and age, controlling for the other factors and restricting the race analyses to categories with more than 1,000 DLBCL survivors to minimize the risk of unstable estimates.

Results:
Among 72,788 DLBCL survivors (median age 66 years; 56.7% male; 66% White; 15% Hispanic; 12% Asian; 6% Black), 5,630 (7.7%) developed a solid SPM over a median follow-up of 105 months. Of the patients who developed a solid SPM, 61% were male, 75% were ≥65, 77% were non-Hispanic White. The overall standardized incidence ratio (SIR) for solid SPMs was elevated at 1.15 [95% CI: 1.12-1.18]. Elevated SIRs were observed for endocrine (2.30 [1.98-2.66]), oral cavity/pharynx (1.68 [1.47-1.91]), melanoma (1.32 [1.19-1.46]), urinary (1.24 [1.15-1.34]), digestive (1.22 [1.15-1.28]), and respiratory system (1.21 [1.13-1.29]) SPMs. Digestive system cancer and melanoma showed consistently elevated SIRs across all time intervals (range: 1.39-1.14 and 1.65-1.27 respectively). Of these system SPMs, all demonstrated elevated risk even in the late surveillance period as reflected by an elevated SIR during the 120+ month period. Only oral cavity and pharynx and respiratory system SPMs did not have an elevated SIR in the earliest surveillance period of 6-11 months. Oral cavity and pharynx SPM SIRs were elevated in the later period of surveillance (60-119 months and 120+ months. There were no significant elevations of SIRs for solid SPMs based on gender, race, or age (<65 and ≥65).

Conclusions:
SPMs are a significant cause of morbidity and mortality among lymphoma survivors. DLBCL survivors are known to be at an increased risk for both hematologic and solid SPMs. In our study focusing on solid SPMs, we found that the SIRs for SPMs varied over time, across cancers, however not by patient demographics. These trends in elevations in SIRs could indicate SPM risk over time as an effect of the natural course of DLBCL or treatment given. Further research is needed on how the interaction between DLBCL therapy and patient’s risk factors influence the risk of SPMs during DLBCL surveillance.

Merry Zhai, MD: No relevant conflicts of interest to declare.